Rocky Mountain Cancer Centers is proud to offer a theranostic approach to treat some cancers. Theranostics describes the process of using a diagnostic radiopharmaceutical to diagnose the cancer and using a similar radiopharmaceutical to treat the cancer. We are able to treat what we see and see what we treat by using this approach.
One example is the use of Gallium 68 PSMA (Prostate-Specific Membrane Antigen) to image the extent of prostate cancer. We then use Lutetium 177 PSMA to treat the cancer. The PSMA ligand leads the imaging or treatment component to the cells of the cancer.
Another use of theranostics is one that has been commercially available for the past few years. This example uses Gallium 68 or Copper 64 Dotatate to image the extent of neuroendocrine cancer and the uses Lutetium 177 Dotatate to treat these patients. Like the PSMA ligand, the Dotatate leads the imaging or treatment component to the cells of the cancer.
We have proven that we are committed to providing personalized theranostic medicine by building a Theranostics Suite at our Denver - Midtown location. This suite includes our PET and CT imaging area as well as our Radionuclide Therapy Suite. The Radionuclide Therapy Suite has the capacity to treat up to four patients at a time. Our experienced staff of nuclear medicine technologists and nuclear medicine physicians can treat over 20 patients per day depending on the type of radionuclide therapy.
We are currently a leader in the treatment of neuroendocrine tumors and plan to treat more prostate cancer patients per week than any other Colorado facility. We do this while providing the cost benefits of a non-hospital-based facility.
We are committed to patient and staff safety. The suite contains a significant amount of lead lining in order to keep the amount of radiation to our staff and patients as low as reasonably achievable.
F18-Pylarify (Lantheus): FDA-approved in May 2021. Projected to be available at RMCC in late 2021/early 2022.
Ga68-PSMA (Telix): Projected FDA approval in late August/early September 2021. Projected to be available at RMCC in mid-September 2021.
Lu177-PSMA (Novartis): Projected FDA approval in mid 2022 (not yet submitted for FDA approval). Projected to be available at RMCC in mid 2022.
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition)
177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer (PSMAfore)